曼谷Bangrak性病中心2018-2023年淋球菌耐药监测及耐药株全基因组测序
研究分析了2018-2023年泰国曼谷Bangrak性病中心分离的765株淋球菌对五种抗菌药物的耐药情况,并对头孢曲松、头孢克肟和/或阿奇霉素耐药株进行全基因组测序。结果显示头孢曲松、头孢克肟和阿奇霉素耐药率分别为0.5%、0.8%和1.7%,但2018-2023年间这三种药物耐药性均已出现且呈上升趋势,所有头孢曲松耐药株均携带penA-60.001。
要点
- 2018-2023年曼谷淋球菌对头孢曲松、头孢克肟、阿奇霉素耐药率分别为0.5%、0.8%、1.7%。
- 头孢曲松耐药株首次于2023年检出(n=3,1.2%),均同时耐头孢克肟且携带penA-60.001。
- 阿奇霉素耐药株2020年首次出现(n=1,0.9%),2023年增至9株(3.7%)。
核心结论
- 曼谷 circulating 淋球菌已出现对头孢曲松、头孢克肟和阿奇霉素的耐药,且耐药性呈上升趋势。
- 对最后单药或双药治疗方案的耐药强调需加强全国培养和基因组监测,并实施新型口服药物zoliflodacin和gepotidacin。
研究设计与样本
- 2018-2023年在泰国曼谷Bangrak性病中心采集男性、女性和跨性别女性生殖道及生殖外拭子进行淋球菌培养。
- 共培养出765株淋球菌,来自739例患者。
- 采用Etest(五种抗菌药物)和EUCAST折点(v16.0)或纸片扩散法(环丙沙星)测定耐药性。
- 对头孢曲松、头孢克肟和/或阿奇霉素耐药株使用Illumina NextSeq 550进行全基因组测序。
主要发现
- 2018-2023年分离的765株淋球菌对头孢曲松、头孢克肟、阿奇霉素、四环素和环丙沙星的耐药率分别为0.5%、0.8%、1.7%、83.7%和95.7%。
- 头孢曲松耐药株首次于2023年检出(n=3,1.2%),且均同时对头孢克肟耐药。
- 其他头孢克肟耐药株于2022年发现(n=2,1.4%)。
- 阿奇霉素耐药株2020年首次出现(n=1,0.9%),2023年增至9株(3.7%)。
- 所有头孢曲松耐药株均含penA-60.001,头孢克肟耐药还可由penA-34.019和penA-10.001导致;所有阿奇霉素耐药株均有23S rRNA突变和/或嵌合/半嵌合MtrD。
关键数值与推荐
- 耐药判定采用EUCAST折点(v16.0)或纸片扩散法(环丙沙星)。
- 头孢曲松耐药率0.5%,头孢克肟耐药率0.8%,阿奇霉素耐药率1.7%,四环素耐药率83.7%,环丙沙星耐药率95.7%。
临床怎么用
- 临床应关注泰国曼谷地区淋球菌对头孢曲松、头孢克肟和阿奇霉素的耐药上升趋势。
- 对淋病患者分离株应加强培养和基因组监测,以发现多重耐药和广泛耐药株。
- 考虑实施新型口服治疗药物zoliflodacin和gepotidacin以应对耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a global public health concern, particularly due to increasing resistance to the last remaining monotherapy, ceftriaxone, in several Asian countries. We examined the AMR of gonococcal isolates obtained at the Bangrak STIs Center, Bangkok, Thailand in 2018-23, and used WGS on isolates resistant to ceftriaxone, cefixime and/or azithromycin. METHODS: Genital and extragenital swabs from males, females and transgender women were cultured. Etest (five antimicrobials) and EUCAST breakpoints (v16.0), or disc diffusion method (ciprofloxacin) were used to determine AMR. WGS was performed using Illumina NextSeq 550. RESULTS: In 2018-23, 765 gonococcal isolates from 739 patients were cultured. Resistance to ceftriaxone, cefixime, azithromycin, tetracycline and ciprofloxacin was 0.5%, 0.8%, 1.7%, 83.7% and 95.7%, respectively. Ceftriaxone-resistant isolates, all resistant also to cefixime, were first detected in 2023 (n = 3, 1.2%). Additional cefixime-resistant isolates were found in 2022 (n = 2, 1.4%). Azithromycin-resistant isolates first emerged in 2020 (n = 1, 0.9%) and increased to nine (3.7%) isolates in 2023. All ceftriaxone-resistant isolates contained penA-60.001, but cefixime resistance was additionally caused by penA-34.019 and penA-10.001. All azithromycin-resistant isolates had 23S rRNA mutations and/or mosaic/semi-mosaic MtrD (subunit of the MtrCDE efflux pump). CONCLUSIONS: Resistance to ceftriaxone, cefixime and azithromycin has emerged in gonococcal strains circulating in Bangkok, Thailand, and resistance appears to be increasing. Resistance to these last options for monotherapy or dual therapy emphasize the need for strengthened national culture-based and genomic surveillance to prevent the spread of MDR and XDR strains in Thailand and globally, and implementation of the novel oral treatments, i.e. zoliflodacin and gepotidacin.
引用
- Paopang P, Sangprasert P, Golparian D, et al. Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018-23. J Antimicrob Chemother. 2026. PMID: 42550164. doi:10.1093/jac/dkag260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。